Progression after first-line aromatase inhibitor plus CDK4/6 inhibitor has become one of the most important decision points in metastatic hormone receptor–positive, HER2-negative breast cancer. This is no longer a setting where clinicians simply move from one endocrine therapy to another. The second-line choice now depends on resistance biology, disease tempo, prior tolerability, HER2 expression, and patient priorities.
The most important message is clear: NGS testing is mandatory after progression on AI plus CDK4/6 inhibitor. Without molecular reassessment, clinicians may miss ESR1 mutations, PI3K/AKT/PTEN pathway alterations, BRCA/PALB2-associated DNA repair deficiency, or HER2-low/HER2-ultralow expression that can completely change the treatment pathway.
Why Progression After AI Plus CDK4/6 Is Biologically Different
First-line AI plus CDK4/6 inhibition remains a major standard in HR-positive, HER2-negative metastatic breast cancer. But once progression occurs, the tumor has often changed. Some tumors remain endocrine-sensitive but acquire a targetable resistance alteration. Others become endocrine-refractory and need antibody-drug conjugates or chemotherapy.
This distinction matters because an endocrine-based second line is still appropriate for many patients, especially when the disease is clinically stable and there is no visceral crisis. But for rapidly progressive, symptomatic, or endocrine-resistant disease, forcing another endocrine line can delay more active treatment.
The First Step: Organize NGS Testing
At progression, testing should be organized immediately. A practical approach includes ctDNA testing because it can rapidly detect acquired resistance mutations, especially ESR1, and tissue biopsy when feasible, especially if HER2 reassessment or histologic transformation is clinically relevant.
The minimum molecular checklist includes ESR1, PIK3CA, AKT1, PTEN, germline BRCA1/2, PALB2, and reassessment of HER2-low or HER2-ultralow status. Broader NGS can also identify rare actionable findings, although these are less common in this setting.
ESR1-Mutated Disease: Oral SERDs and ER Degraders Move Forward
ESR1 mutations are common after aromatase inhibitor exposure and are one of the clearest examples of acquired endocrine resistance. In ESR1-mutated disease, continuing an AI usually makes little biological sense. The better strategy is to target the estrogen receptor directly.
Elacestrant was approved for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy. In EMERALD, all patients were required to have prior CDK4/6 inhibitor exposure, and among patients with ESR1-mutated tumors, median PFS was 3.8 months with elacestrant versus 1.9 months with standard endocrine therapy, with an HR of 0.55. Key toxicities include nausea, musculoskeletal pain, hyperlipidemia, fatigue, liver enzyme abnormalities, vomiting, diarrhea, and appetite loss.
Vepdegestrant has now added another ESR1-directed option. The FDA approved vepdegestrant on May 1, 2026, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy. In VERITAC-2, patients had progressed on one to two prior endocrine lines, including a CDK4/6 inhibitor; in the ESR1-mutated population, median PFS was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant, with an HR of 0.57, and ORR was 19% versus 4%. The FDA label includes warnings for QTc interval prolongation and embryo-fetal toxicity.
The practical point is that ESR1-mutated progression is now a biomarker-defined endocrine resistance state with real oral options. These are most attractive when disease remains endocrine-sensitive, the patient is clinically stable, and avoiding chemotherapy is a priority.
Read About Approval on OncoDaily Breast
PIK3CA-Mutated Disease: Alpelisib Plus Fulvestrant Remains Important, But Toxicity Drives Selection
For patients with PIK3CA-mutated HR-positive, HER2-negative metastatic breast cancer, alpelisib plus fulvestrant remains a relevant second-line option, particularly when the patient is fit and metabolic risk is manageable. The FDA approved alpelisib with fulvestrant for postmenopausal women and men with PIK3CA-mutated advanced or metastatic HR-positive, HER2-negative breast cancer after progression on or after endocrine therapy. In SOLAR-1, median PFS in the PIK3CA-mutated cohort was 11.0 months with alpelisib plus fulvestrant versus 5.7 months with placebo plus fulvestrant.
The main issue is toxicity. Alpelisib requires active management of hyperglycemia, rash, diarrhea, nausea, fatigue, and weight loss. Baseline HbA1c, diabetes history, body mass index, and patient willingness to monitor glucose are not details; they are central to whether this is the right drug. In a patient with uncontrolled diabetes or high frailty, a different targeted option may be more reasonable even if PIK3CA is present.
Read About PIK3CA Testing on OncoDaily
PIK3CA, AKT1, or PTEN-Altered Disease: Capivasertib Plus Fulvestrant Broadens the Pathway Approach
Capivasertib plus fulvestrant is one of the most useful post-AI options because it covers a broader pathway: PIK3CA, AKT1, and PTEN alterations. The FDA approved capivasertib with fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations after progression on at least one endocrine-based regimen. In CAPItello-291, patients were required to have progression on aromatase inhibitor-based treatment; in the altered population, median PFS was 7.3 months versus 3.1 months, with an HR of 0.50.
The practical appeal is that capivasertib may be relevant when the tumor has AKT pathway activation beyond PIK3CA alone. Salient toxicities include diarrhea, rash, hyperglycemia, nausea, fatigue, and stomatitis. Compared with alpelisib, the metabolic toxicity profile is often viewed as more manageable, but rash and diarrhea still require early intervention.
HER2-Low and HER2-Ultralow Disease: Recheck HER2 Because It Now Changes Treatment
HER2 status should be reassessed after progression, because HER2-low and HER2-ultralow disease are now treatment-relevant categories. The FDA approved trastuzumab deruxtecan for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer that has progressed on one or more endocrine therapies in the metastatic setting. In DESTINY-Breast06, the trial excluded patients with prior chemotherapy for advanced/metastatic disease, and median PFS was 13.2 months with trastuzumab deruxtecan versus 8.1 months with physician’s choice chemotherapy in HER2-low disease; in the overall HER2-low/ultralow population, median PFS was also 13.2 versus 8.1 months, with an HR of 0.64.
This is one of the biggest changes in the post-CDK4/6 landscape. T-DXd can now enter before conventional chemotherapy for eligible HR-positive HER2-low/ultralow metastatic breast cancer after endocrine progression, depending on regulatory setting and patient context. The main toxicity that must be respected is interstitial lung disease/pneumonitis. Nausea, cytopenias, fatigue, alopecia, diarrhea, and liver enzyme changes are also common, but ILD is the toxicity that requires systematic education, early imaging, drug interruption, and steroid management when suspected.
Read About HER2-Low Breast Cancer on OncoDaily
BRCA and PALB2: Do Not Miss DNA Repair Deficiency
If germline BRCA1/2 status is unknown, testing should be completed. PALB2 and other homologous recombination alterations also matter, although approvals and access vary by region. PARP inhibitors such as olaparib and talazoparib are important targeted options for germline BRCA-associated metastatic breast cancer and can be particularly attractive when the patient prefers an oral therapy and has not previously received a PARP inhibitor.
The main toxicities are anemia, neutropenia, fatigue, nausea, and thrombocytopenia, with rare but important long-term risks such as MDS/AML. These drugs are often better tolerated than chemotherapy, but blood count monitoring is essential.
Read About BRCA Mutations on OncoDaily
If No Actionable Mutation Is Found: Endocrine Therapy Still Has a Role, But Only in the Right Patient
Not every patient will have an actionable finding. If disease progression is slow, symptoms are limited, and there is no visceral crisis, endocrine-based therapy can still be reasonable. Fulvestrant-based therapy, everolimus-based combinations, or clinical trial enrollment may be considered.
Everolimus plus exemestane remains an option, especially where newer targeted drugs are unavailable or unsuitable. Its use after CDK4/6 inhibitors is based more on extrapolation and real-world practice than on the modern strength of evidence seen with newer biomarker-matched approaches. Toxicities include stomatitis, fatigue, rash, hyperglycemia, hyperlipidemia, infections, and noninfectious pneumonitis, so prophylactic mouth care and early toxicity management are important.
When to Move Beyond Endocrine Therapy
The most important clinical judgment is deciding when endocrine therapy is no longer enough. Red flags include short first-line benefit, rapid progression, multiple new visceral lesions, worsening symptoms, rising disease burden, or impending organ dysfunction.
In this situation, ADCs or chemotherapy should move earlier. For HER2-low or HER2-ultralow disease, trastuzumab deruxtecan is now a major option. For later-line HR-positive/HER2-negative disease, sacituzumab govitecan has proven benefit after endocrine therapy and at least two additional systemic therapies in the metastatic setting. In TROPiCS-02, the FDA summary reports median PFS 5.5 versus 4.0 months and median OS 14.4 versus 11.2 months compared with single-agent chemotherapy. Common toxicities include neutropenia, anemia, diarrhea, fatigue, nausea, alopecia, and leukopenia.
Conventional chemotherapy still has a role, especially when there is visceral crisis or rapid symptomatic progression. Common options include capecitabine, taxanes, eribulin, vinorelbine, gemcitabine, and liposomal doxorubicin depending on prior exposure, comorbidities, and patient goals. The difference today is that chemotherapy is no longer the automatic second-line answer for every patient.
Read About Trastuzumab Deruxtecan on OncoDaily
A Practical Treatment Framework After AI Plus CDK4/6
A clean way to approach this setting is to divide patients into three groups.
The first group is endocrine-sensitive with an actionable biomarker. These patients are usually best served by matched therapy: elacestrant or vepdegestrant for ESR1 mutation, capivasertib plus fulvestrant for PIK3CA/AKT1/PTEN alteration, alpelisib plus fulvestrant for PIK3CA mutation in metabolically appropriate patients, or a PARP inhibitor for germline BRCA-associated disease.
The second group is endocrine-sensitive without a clear biomarker. These patients may still receive fulvestrant-based or everolimus-based therapy, but clinical trial enrollment is especially valuable.
The third group is endocrine-refractory or clinically aggressive disease. These patients should be considered for ADC-based therapy, especially trastuzumab deruxtecan if HER2-low/ultralow, or chemotherapy when immediate disease control is required.
The Key Takeaway
Second-line treatment after AI plus CDK4/6 inhibitor is now a biomarker-driven decision. The old question was, “Which endocrine therapy comes next?” The modern question is, “What resistance mechanism is driving this progression, and do we have a targeted way to treat it?”
The answer begins with mandatory NGS testing and HER2 reassessment. ESR1 mutations open the door to oral ER-directed therapy. PIK3CA/AKT1/PTEN alterations support pathway inhibition. HER2-low and HER2-ultralow expression can make trastuzumab deruxtecan highly relevant. BRCA and PALB2 alterations point toward PARP inhibition. When biology no longer supports endocrine therapy, ADCs and chemotherapy become essential.
In metastatic breast cancer, second-line treatment is no longer just the next step. It is the moment where precision oncology must be actively organized.